Dr. Stefanie Morgan has joined the TimeWarp Science Advisory Board

We are excited to welcome Dr. Stefanie Morgan to the TimeWarp Labs Scientific Advisory Board.

Stefanie is a Stanford-trained researcher in longevity and the Vice President of Research and Applied Sciences at AgelessRx. Her work focuses on translating geroscience into real-world human data, with a particular emphasis on safety, dosing, and clinical decision-making.

She is the corresponding author of the PEARL trial, one of the first year-long randomized studies of low-dose intermittent rapamycin in healthy aging adults, and has led major investigations into rapamycin bioavailability and blood level dynamics.

Why this matters for TimeWarp: Stefanie bridges rigorous aging biology with real human evidence, helping shape formulations and protocols that are both scientifically sound and clinically responsible.

We are thrilled to have her perspective guiding our work.